
Feline Medicine
Latest News
Latest Videos

Shorts










Podcasts
CME Content
More News

Hill’s Pet Nutrition releases first kitten-focused report to support early-life development and care
The report designates the first 12 months of a cat's life as a critical pediatric period, with implications for nutrition, vaccination timing, early sterilization, and shelter foster programs.

The new formula aims to address two common issues simultaneously.

After years of off-label use, veterinarians now have the first FDA-approved amlodipine formulation specifically indicated for cats with systemic hypertension.

Researchers have created the first large-scale genetic map of feline cancer, sequencing nearly 500 tumors across 13 cancer types and uncovering actionable mutations that could guide treatment in both cats and people.

A weekly look at the stories shaping veterinary medicine—from emerging outbreaks and policy shifts to scientific advances and industry news—all delivered in under five minutes.

New study results from Gallant show that 76% of cats improved after receiving intravenous uterine-derived mesenchymal stromal cell therapy, an immune-modulating treatment that doesn't require patient-derived cells.

In this Q&A, Tiffany Tupler, DVM, CBCC-KA, HAB, outlines a 4-part framework for addressing behavioral concerns and explains why early, proactive conversations matter.

In this Q&A, Tiffany Tupler, DVM, CBCC-KA, HABc, breaks down the feline behaviors that are most commonly misread by owners, as well as the role veterinary teams can play in setting the record straight.

Commentary: The hidden harm of inappropriate language about cats in veterinary and social media spaces
The authors discuss feline behavior and how negative labels can influence patient care.

CKD in cats is often linked to aging, but a veterinarian explains how genetics, prior illness, urinary tract issues, and even geographic location may also increase risk.

The drug product from Cronus Pharma is indicated to control pain and inflammation associated with surgery in companion animals.

An outbreak of canine distemper virus killed 72 tigers at a popular tourist attraction in Thailand, ruling out earlier concerns about avian influenza and raising questions about disease risks in captive tiger populations.

FDA issues EUA for product to treat New World screwworm in canine and feline patients
The afoxolaner chewable tablet is the most recent drug to receive an EUA from the FDA to treat New World screwworm in feline and canine patients.

Patent ductus arteriosus is a congenital heart defect that requires timely surgery.

A fatal highly pathogenic avian influenza infection in a domestic cat linked to wildlife and a separate backyard poultry detection point to ongoing spillover risks for animals sharing outdoor environments.

Royal Canin unveils a new diet for cats with diabetes and home care kits at VMX 2026.

Robenacoxib tablets from ZyVet Animal Health are bioequivalent to Onsior (Elanco Animal Health).

The product from Virbac contains ursolic acid that inhibits messenger RNA expression changes associated with muscle atrophy.

Inflammatory bowel disease (IBD) may progress to feline small cell gastrointestinal (GI) lymphoma, researchers say. Texas A&M University is testing a new treatment option for the cancer.

Why do cat wag their tails? Annie Valuska, PhD, explains this behavioral cue and more in a dvm360 interview.

Virbac acquired an oral solution of methimazole, known as Felanorm in the US and Thyronorm outside the US. The drug is the first FDA-approved generic methimazole oral solution for hyperthyroidism in cats.

Interpreting feline behaviors (Part 1)
What does it mean when a cat hisses? Annie Valuska, PhD, explaine in a dvm360 interview.

FelineVMA is providing the resource that was authored by a task force of board-certified veterinary specialists and a veterinary technician specialist in dentistry.

The monoclonal antibody from Zoetis previously received marketing authorization in Europe.

Cornell University is enrolling client-owned cats in an 11-week trial of AKS-562c, a once-weekly GLP-1 Fc-fusion candidate designed to reduce appetite and produce clinically meaningful weight loss while closely monitoring safety and tolerability.























